AnalystsLuca IssiLuca Issi's Stock Forecasts
AnalystsLuca Issi
Sectors:
Industries:
Analyst Ranking
Top 9%
#431 out of 5134 analysts
Average Return
+13.26%
Win Rate
52%73 out of 140
Risk vs Reward
Poor
Good
Luca Issi's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Arrowhead Pharmaceuticals IncARWR | +274.18% | $16.42 | $61.44 | 2025-08-08 - 2025-12-05 | Buy |
Uniqure NvQURE | +263.97% | $7.16 | $26.06 | 2024-11-06 - 2025-11-05 | Buy |
Arrowhead Pharmaceuticals IncARWR | +225.25% | $18.89 | $61.44 | 2025-02-11 - 2025-12-05 | Buy |
4d Molecular Therapeutics IncFDMT | +158.45% | $4.14 | $10.70 | 2025-03-03 - 2025-12-05 | Buy |
Ionis Pharmaceuticals IncIONS | +149.86% | $32.69 | $81.68 | 2025-02-20 - 2025-12-05 | Buy |
Luca Issi Analyst Color
Get additional color on Luca Issi's coverage of popular stocks
Luca Issi's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Moderna IncMRNA | 18 | Hold | $25.00 | -9.75% | Maintains | 17 days ago |
Agios Pharmaceuticals IncAGIO | 1 | Hold | $28.00 | +0.97% | Downgrades | 18 days ago |
Arrowhead Pharmaceuticals IncARWR | 10 | Buy | $52.00 | -15.36% | Maintains | 19 days ago |
Korro Bio IncKRRO | 8 | Hold | $8.00 | +13.96% | Downgrades | 25 days ago |
Crispr Therapeutics AgCRSP | 14 | Hold | $50.00 | -12.10% | Maintains | a month ago |
Regenxbio IncRGNX | 10 | Buy | $19.00 | +44.38% | Maintains | a month ago |
Intellia Therapeutics IncNTLA | 7 | Hold | $9.00 | -6.35% | Maintains | a month ago |
Dyne Therapeutics IncDYN | 4 | Buy | $30.00 | +47.93% | Maintains | a month ago |
Uniqure NvQURE | 7 | Buy | $45.00 | +110.97% | Maintains | a month ago |
Argenx SeARGX | 2 | Buy | $860.00 | -4.57% | Maintains | a month ago |
Ionis Pharmaceuticals IncIONS | 10 | Buy | $82.00 | +0.39% | Maintains | a month ago |
Fulcrum Therapeutics IncFULC | 2 | Hold | $7.00 | -21.35% | Maintains | a month ago |
Avidity Biosciences IncRNA | 3 | Hold | $72.00 | +0.52% | Downgrades | a month ago |
Alnylam Pharmaceuticals IncALNY | 27 | Buy | $500.00 | +9.14% | Maintains | 3 months ago |
Ascendis Pharma AASND | 3 | Buy | $230.00 | +11.95% | Maintains | 4 months ago |
Adverum Biotechnologies IncADVM | 8 | Hold | $4.00 | -6.10% | Maintains | 7 months ago |
Allogene Therapeutics IncALLO | 8 | Buy | $10.00 | +599.30% | Reiterates | 7 months ago |
Apellis Pharmaceuticals IncAPLS | 7 | Hold | $18.00 | -23.83% | Maintains | 7 months ago |
Lexeo Therapeutics IncLXEO | 5 | Buy | $20.00 | +113.90% | Maintains | 8 months ago |
Sangamo Therapeutics IncSGMO | 6 | Hold | $2.00 | +303.23% | Reiterates | 9 months ago |
Ocular Therapeutix IncOCUL | 1 | Buy | $17.00 | +35.14% | Initiates Coverage On | 9 months ago |
Meiragtx Holdings PLCMGTX | 6 | Buy | $13.00 | +50.29% | Maintains | 9 months ago |
Verve Therapeutics IncVERV | 7 | Buy | $15.00 | +34.77% | Maintains | 9 months ago |
4d Molecular Therapeutics IncFDMT | 7 | Buy | $35.00 | +227.10% | Maintains | 9 months ago |
Beam Therapeutics IncBEAM | 7 | Hold | $26.00 | -4.02% | Maintains | 9 months ago |
Biomarin Pharmaceutical IncBMRN | 12 | Hold | $70.00 | +31.09% | Reiterates | 10 months ago |
Slb LimitedSLB | 1 | Buy | $57.00 | +48.21% | Reiterates | a year ago |
Editas Medicine IncEDIT | 8 | Hold | $4.00 | +65.29% | Maintains | a year ago |
Bluebird Bio IncBLUE | 4 | Hold | $80.00 | N/A | Reiterates | a year ago |
Ultragenyx Pharmaceutical IncRARE | 3 | Buy | $77.00 | N/A | Reiterates | a year ago |
Wave Life Sciences LtdWVE | 5 | Hold | $15.00 | N/A | Maintains | a year ago |
Caribou Biosciences IncCRBU | 5 | Buy | $14.00 | N/A | Reiterates | a year ago |
Lenz Therapeutics IncLENZ | 3 | Hold | $3.00 | N/A | Maintains | 3 years ago |
Q32 Bio IncQTTB | 3 | Hold | $54.00 | N/A | Maintains | 3 years ago |
Dicerna Pharmaceuticals IncDRNA | 2 | Hold | $38.25 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.